1. Home
  2. PHAR vs SPTN Comparison

PHAR vs SPTN Comparison

Compare PHAR & SPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • SPTN
  • Stock Information
  • Founded
  • PHAR 1988
  • SPTN 1917
  • Country
  • PHAR Netherlands
  • SPTN United States
  • Employees
  • PHAR N/A
  • SPTN N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • SPTN Food Distributors
  • Sector
  • PHAR Health Care
  • SPTN Consumer Discretionary
  • Exchange
  • PHAR Nasdaq
  • SPTN Nasdaq
  • Market Cap
  • PHAR 718.1M
  • SPTN 596.4M
  • IPO Year
  • PHAR N/A
  • SPTN N/A
  • Fundamental
  • Price
  • PHAR $10.27
  • SPTN $26.60
  • Analyst Decision
  • PHAR Strong Buy
  • SPTN Hold
  • Analyst Count
  • PHAR 3
  • SPTN 1
  • Target Price
  • PHAR $30.00
  • SPTN $26.90
  • AVG Volume (30 Days)
  • PHAR 4.3K
  • SPTN 1.3M
  • Earning Date
  • PHAR 07-31-2025
  • SPTN 08-14-2025
  • Dividend Yield
  • PHAR N/A
  • SPTN 3.27%
  • EPS Growth
  • PHAR N/A
  • SPTN N/A
  • EPS
  • PHAR N/A
  • SPTN N/A
  • Revenue
  • PHAR $320,708,000.00
  • SPTN $9,652,685,000.00
  • Revenue This Year
  • PHAR $13.31
  • SPTN $6.00
  • Revenue Next Year
  • PHAR $7.68
  • SPTN N/A
  • P/E Ratio
  • PHAR N/A
  • SPTN N/A
  • Revenue Growth
  • PHAR 24.13
  • SPTN 0.26
  • 52 Week Low
  • PHAR $6.65
  • SPTN $17.30
  • 52 Week High
  • PHAR $12.61
  • SPTN $26.65
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 48.21
  • SPTN 78.13
  • Support Level
  • PHAR $10.46
  • SPTN $26.37
  • Resistance Level
  • PHAR $11.49
  • SPTN $26.56
  • Average True Range (ATR)
  • PHAR 0.37
  • SPTN 0.29
  • MACD
  • PHAR -0.12
  • SPTN 0.60
  • Stochastic Oscillator
  • PHAR 27.62
  • SPTN 99.45

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About SPTN SpartanNash Company

SpartanNash Co is a food solutions company that delivers the ingredients. Its principal business activities include, distributing grocery products to a diverse group of independent and chain retailers, its corporate-owned retail stores, and U.S. military commissaries and exchanges; as well as operating a fresh produce distribution network and the Our Family private label brand. The company operates in two segments: Retail and Wholesale. Majority of the revenue is earned from its Wholesale segment which uses a multi-channel sales approach to distribute national brand and private brand products to independent retailers, national accounts, food service distributors, e-commerce providers, and the Company's corporate owned retail stores.

Share on Social Networks: